Reuters logo
BRIEF-Meridian Bioscience comments on recent FDA posting related to Magellan Diagnostics
June 6, 2017 / 9:58 PM / in 5 months

BRIEF-Meridian Bioscience comments on recent FDA posting related to Magellan Diagnostics

June 6 (Reuters) - Meridian Bioscience Inc:

* Meridian Bioscience comments on recent fda posting related to Magellan Diagnostics

* Meridian bioscience-“we continue to work with fda” and do not expect the recall “to cause any material adverse effect to meridian’s financial results” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below